Pythia Biosciences and Miraomics to Build a High-Quality Single-Cell Database for Drug Research and AI/ML Acceleration

SAN DIEGO, California — May 22, 2025 — Pythia Biosciences and Miraomics today announced a strategic collaboration to develop Pythiomics—a rich, high-quality and harmonized single-cell omics database designed to accelerate discoveries and AI/ML development in drug research. Pythiomics combines expert manual curation, rigorous quality control, metadata harmonization, and cutting-edge AI techniques for cell type annotation. The result is a standardized, reliable, and accessible data resource that enables biopharmaceutical companies and research institutions to validate insights, develop AI/ML models, and accelerate target and biomarker discoveries.

Despite the explosion of single-cell datasets in recent years, much of the data are stored in inconsistent formats and annotated with non-standardized metadata, while scattering across different repositories. These issues make curation, integration and analysis time-consuming and costly—often placing the power of single-cell data out of reach for many research efforts.

To solve this, Pythia Biosciences and Miraomics have partnered to build Pythiomics with a focus on scientific rigor and usability. The database follows a step-by-step standard operating process (SOP) to ensure rigorous quality control, metadata harmonization and comprehensive documentation for traceability. AI-powered tools are employed to assist in accurate cell type annotation and metadata harmonization, while all data is mapped to widely adopted public and proprietary ontologies.

As of May 2025, Pythiomics comprises 107 million cells spanning hundreds of disease subtypes and incorporating more than 20 standardized vocabularies. The database can be accessed via the C-DIAM Multi-Omics Studio, a web-based platform developed by Pythia Biosciences that supports interactive exploration of multi-omics datasets—including single-cell, CITE-seq, Visium, Visium HD, Xenium, bulk RNA-seq, proteomics, and metabolomics data. Pythiomics is also available via AWS S3 delivery.

“The challenges of harmonisation, annotation and accessibility of multi-omic data create a major bottleneck in addressing critical scientific questions. Our collaboration is a pivotal step towards addressing this issue and unlocking this critical resource, enabling researchers to accelerate drug discovery and innovation,” remarked Dr. Eugene Bolotin, CEO of Miraomics.

“Miraomics brings unparalleled expertise in leveraging both in-house and vendor data to drive drug discovery and development in Pharma. Recognizing that data quality is paramount and understanding where other data sources have fallen short, they have played a pivotal role in establishing optimal standard operating procedures to ensure we generate the highest-quality data possible.” said Tristan Gill, CEO of Pythia Biosciences. “By combining Pythia and Miraomic’s deep knowledge of data curation with advanced AI tools, we are making significant strides in harmonizing complex datasets and empowering the research community.”

In addition to single-cell transcriptomics data, the Pythiomics database also incorporates multi-omics data, including proteomics, bulk RNA-seq, and metabolomics - totaling more than 10,000 datasets. This integration enables scientists to cross-validate insights across omics layers, offering a holistic perspective on disease mechanisms and therapeutic opportunities.

To learn more about the collaboration and upcoming disease areas to be added to the Pythiomics database, visit www.pythiabio.com or https://miraomics.bio.

—---------------

About Pythia Biosciences

Every scientist is important because every patient is important.

Pythia Biosciences was founded to empower scientists in tackling the biggest challenges in multi-omics data analysis. The company builds advanced software solutions and provides full-spectrum bioinformatics services. Its flagship product, the C-DIAM Multi-Omics Studio, allows researchers to analyze, visualize, and integrate diverse datasets—including single-cell multi-omics, spatial transcriptomics, proteomics, and metabolomics—through interactive analytics and modern visualizations, revealing a more complete picture of biological systems. For more information, visit https://pythiabio.com

About Miraomics

Truly understand your data.

Miraomics is a full-service analytics company specializing in high-throughput bioinformatics and data science for the life sciences. The company provides end-to-end solutions for processing, analyzing, and visualizing omics data—including genomics, transcriptomics, and other molecular platforms—supporting academic, biotech, and clinical clients. With deep expertise in statistical modeling, custom pipeline development, and integrative analysis, Miraomics empowers researchers and organizations to transform complex biological data into actionable insights, driving discovery and innovation in biomedical research and precision medicine. For more information, visit https://miraomics.bio